$WAT

KeyBanc raises Waters stock price target to $500 on guidance boost

KeyBanc raised its price target for Waters Corp. (WAT) to $500 from $460, citing strong Q3 results and raised guidance. WAT reported 10% revenue growth and 30.1% adjusted operating margin, exceeding estimates. The stock is up 52% in six months, trading near $460. Stifel also raised its target to $470 but maintained a Hold rating. WAT's full-year guidance was increased to 9.1%-9.7% growth, with AI and China growth cited as positive factors.

Original reporting
Published Nov 4, 2026, 2:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 2:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$WAT
Bullish
high confidence
Mentioned
$WAT
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$WATBullishMed
01

Why it matters

The guidance lift and higher price target could drive short‑term buying pressure, but valuation concerns remain.

02

Market read

Fresh earnings beat and guidance raise for Waters provide a new catalyst for the stock, offering a medium‑term trade idea.

03

What to watch

Potential slowdown in China demand and the exclusion of reshoring assumptions from guidance.

Relevance 7/10Novelty 7/10Timing: today

Background

Waters Corp. (NYSE:WAT) provides analytical instruments; its Q3 2026 results beat expectations and prompted multiple analyst target raises.

Company-level read

Ticker impact

$WATBullishHigh confidence
Context

KeyBanc raised its price target to $500 after Waters Corp. reported Q3 revenue and earnings beat and raised full-year guidance.

Expected impact

likely upward pressure as investors price in the stronger guidance and target raise

Evidence & confidence

Guidance lift and price‑target increase are fresh, material news for a mid‑cap company; the stock is already near its 52‑week high, so the catalyst may sustain a rally.

Market effects

Positive for the analytical instruments sector as Waters' AI‑driven growth hints at broader demand.

U.S. biotech/chemicals markets may see modest gains from the upbeat guidance.

Limited; primarily affects U.S. investors focused on life‑science equipment.

Counterpoint

The stock may be overvalued near its 52‑week high; the price‑target raise could be premature.

Key entities

  • KeyBanc

    Raised price target to $500 and maintained Overweight rating.

  • Stifel

    Raised price target to $470, Hold rating.

Related articles

$WATHighAI 8/10

Bernstein raises Waters stock price target to $535 on earnings beat

Bernstein raised its price target on Waters Corp. (WAT) to $535 from $450, citing strong Q3 2026 results. Revenue grew 10% in constant currency, and adjusted EPS of $4.10 beat estimates. The company raised full-year 2026 guidance for revenue and EPS. Bernstein described the 2027 outlook as conservative, with mid-single-digit-plus organic growth expected. Other analysts also raised price targets following the earnings beat.

$WATMedAI 8/10

Waters Q3 Earnings Call Highlights

Waters Corporation (WAT) reported Q3 revenue of $575M in Advanced Diagnostics, up 2%, and $500M in Diagnostic Solutions, flat. Microbiology revenue grew 4% outside China but declined 20% in China. Clinical Business Unit revenue rose 17%, and Materials Sciences revenue increased 7%. The company expects to recover revenue from reagent-rental compliance and announced partnerships for its Onclarity HPV kit.